Quantcast

Latest Philadelphia chromosome Stories

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL228 in patients with advanced malignancies (solid tumors, lymphoma, or multiple myeloma) for which standard therapies are no longer effective. XL228 is a potent small molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R) and SRC, which are protein kinases known to promote cancer cell survival, proliferation, and migration. XL228 also inhibits BCR-ABL, a protein kinase...

2008-10-08 09:00:12

EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib mesylate provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in...

2008-08-27 09:00:23

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- Novartis announced today that Gleevec(R) (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST). FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review timing from ten to six months(1)....

2008-07-01 09:01:11

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today that it has submitted the non-clinical section of the rolling submission of a New Drug Application (NDA) for omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) to the U.S. Food and Drug Administration (FDA). "The non-clinical section of the NDA is the first of three parts necessary to complete the NDA submission of omacetaxine and brings us one step closer to commercialization," said Dr. Greg Collier, ChemGenex's...

2008-06-16 12:01:05

Exelixis has reported preliminary Phase I data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. Approximately 17 subjects have received at least one dose of XL228, of whom 16 had completed cycle 1. The trial is evaluating a treatment cycle consisting of four weekly one-hour IV infusions of XL228 at doses...

2008-06-16 09:01:19

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs). These data represent the first findings to be presented from this ongoing study, conducted in patients with or without BCR-ABL mutations. The data presented complement the...

2007-06-22 15:10:42

WHITE PLAINS, N.Y., Jun. 22 /PRNewswire-USNewswire/ -- Neil Shah, M.D., PHD, an expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled The Latest on CML - Update from the American Society of Clinical Oncology (ASCO) Annual Meeting. The program is scheduled for Thursday, Jun. 28, 2007, 12:00 p.m. - 1:30 p.m. ET. Dr. Shah, assistant professor for the division of Hematology/Oncology Department of Medicine at the...

2006-12-06 18:02:44

By ED SUSMAN After five years of treatment nearly 90 percent of leukemia patients treated with Gleevec are still alive -- an outcome barely conceivable before the drug was discovered. The Gleevec story truly is a triumph of science over disease, Brian Druker, the lead investigator of the studies with the anti-cancer drug, told United Press International Wednesday. Druker, professor of medicine at the Oregon Health and Sciences University Cancer Center in Portland, said, The results we...

2006-07-23 14:45:00

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage,...

89d7ddf2b7a291cf1da22844fcc1d77b1
2006-07-23 12:05:00

By Maggie Fox, Health and Science Correspondent WASHINGTON -- Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage, the team...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.